256 related articles for article (PubMed ID: 23860535)
1. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.
Ceresoli GL; Zucali PA; Mencoboni M; Botta M; Grossi F; Cortinovis D; Zilembo N; Ripa C; Tiseo M; Favaretto AG; Soto-Parra H; De Vincenzo F; Bruzzone A; Lorenzi E; Gianoncelli L; Ercoli B; Giordano L; Santoro A
Br J Cancer; 2013 Aug; 109(3):552-8. PubMed ID: 23860535
[TBL] [Abstract][Full Text] [Related]
2. A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
Dowell JE; Dunphy FR; Taub RN; Gerber DE; Ngov L; Yan J; Xie Y; Kindler HL
Lung Cancer; 2012 Sep; 77(3):567-71. PubMed ID: 22770372
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
[TBL] [Abstract][Full Text] [Related]
4. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
Santoro A; O'Brien ME; Stahel RA; Nackaerts K; Baas P; Karthaus M; Eberhardt W; Paz-Ares L; Sundstrom S; Liu Y; Ripoche V; Blatter J; Visseren-Grul CM; Manegold C
J Thorac Oncol; 2008 Jul; 3(7):756-63. PubMed ID: 18594322
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
Patel JD; Hensing TA; Rademaker A; Hart EM; Blum MG; Milton DT; Bonomi PD
J Clin Oncol; 2009 Jul; 27(20):3284-9. PubMed ID: 19433684
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
Buikhuisen WA; Burgers JA; Vincent AD; Korse CM; van Klaveren RJ; Schramel FM; Pavlakis N; Nowak AK; Custers FL; Schouwink JH; Gans SJ; Groen HJ; Strankinga WF; Baas P
Lancet Oncol; 2013 May; 14(6):543-51. PubMed ID: 23583604
[TBL] [Abstract][Full Text] [Related]
7. Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: a realistic treatment option?
Li L; Razak AR; Hughes A
Lung Cancer; 2009 May; 64(2):207-10. PubMed ID: 18926592
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
Ceresoli GL; Zucali PA; Favaretto AG; Grossi F; Bidoli P; Del Conte G; Ceribelli A; Bearz A; Morenghi E; Cavina R; Marangolo M; Parra HJ; Santoro A
J Clin Oncol; 2006 Mar; 24(9):1443-8. PubMed ID: 16549838
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
Castagneto B; Botta M; Aitini E; Spigno F; Degiovanni D; Alabiso O; Serra M; Muzio A; Carbone R; Buosi R; Galbusera V; Piccolini E; Giaretto L; Rebella L; Mencoboni M
Ann Oncol; 2008 Feb; 19(2):370-3. PubMed ID: 18156144
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.
Hughes A; Calvert P; Azzabi A; Plummer R; Johnson R; Rusthoven J; Griffin M; Fishwick K; Boddy AV; Verrill M; Calvert H
J Clin Oncol; 2002 Aug; 20(16):3533-44. PubMed ID: 12177114
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer.
Stevenson JP; Langer CJ; Somer RA; Evans TL; Rajagopalan K; Krieger K; Jacobs-Small M; Dyanick N; Milcarek B; Coakley S; Walker S; Eaby-Sandy B; Hageboutros A
Cancer; 2012 Nov; 118(22):5580-7. PubMed ID: 22544579
[TBL] [Abstract][Full Text] [Related]
13. Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.
Pasello G; Nicotra S; Marulli G; Rea F; Bonanno L; Carli P; Magro C; Jirillo A; Favaretto A
Lung Cancer; 2011 Sep; 73(3):351-5. PubMed ID: 21296448
[TBL] [Abstract][Full Text] [Related]
14. NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status.
Dy GK; Molina JR; Qi Y; Ansari R; Thomas S; Ross HJ; Soori G; Anderson D; Aubry MC; Meyers J; Adjei AA; Mandrekar S; Adjei AA
J Thorac Oncol; 2014 Aug; 9(8):1146-53. PubMed ID: 25157767
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experience.
Malhotra B; Evans T; Weiss J; Eaby B; Stonehouse-Lee S; Sherry V; Langer CJ
Clin Lung Cancer; 2010 May; 11(3):192-7. PubMed ID: 20439196
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.
Katirtzoglou N; Gkiozos I; Makrilia N; Tsaroucha E; Rapti A; Stratakos G; Fountzilas G; Syrigos KN
Clin Lung Cancer; 2010 Jan; 11(1):30-5. PubMed ID: 20085865
[TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116.
Casey EM; Harb W; Bradford D; Bufill J; Nattam S; Patel J; Fisher W; Latz JE; Li X; Wu J; Hanna N
J Thorac Oncol; 2010 Nov; 5(11):1815-20. PubMed ID: 20881647
[TBL] [Abstract][Full Text] [Related]
18. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
Hassan R; Kindler HL; Jahan T; Bazhenova L; Reck M; Thomas A; Pastan I; Parno J; O'Shannessy DJ; Fatato P; Maltzman JD; Wallin BA
Clin Cancer Res; 2014 Dec; 20(23):5927-36. PubMed ID: 25231400
[TBL] [Abstract][Full Text] [Related]
19. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
Taylor P; Castagneto B; Dark G; Marangolo M; Scagliotti GV; van Klaveren RJ; Labianca R; Serke M; Schuette W; van Meerbeeck JP; Heigener D; Liu Y; Adachi S; Blatter J; von Pawel J
J Thorac Oncol; 2008 Jul; 3(7):764-71. PubMed ID: 18594323
[TBL] [Abstract][Full Text] [Related]
20. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.
Ceresoli GL; Castagneto B; Zucali PA; Favaretto A; Mencoboni M; Grossi F; Cortinovis D; Del Conte G; Ceribelli A; Bearz A; Salamina S; De Vincenzo F; Cappuzzo F; Marangolo M; Torri V; Santoro A
Br J Cancer; 2008 Jul; 99(1):51-6. PubMed ID: 18542071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
